Role of Neuraminidase-1 in Cancer Development and Clinical Implications
Loading...
Authors
Haxho, Fiona
Date
Type
thesis
Language
eng
Keyword
Neuraminidase , Growth Factor Receptor , Cellular Signaling , Glycobiology , Receptor Glycosylation , Sialic Acid , Human Cancer
Alternative Title
Abstract
The abnormal expression of cell surface sialic acid has recently been identified as an important trait of cancer cells. The main sialylation-modifying enzyme in mammalian cells, neuraminidase-1 (Neu1), has been shown to positively regulate several receptors and their activation, including the epidermal growth factor receptor (EGFR), insulin receptor (IR), and a number of TOLL-like receptors (TLR). Notably, these receptors each play unique and profound roles in tumor development and progression via promotion of cell proliferation and survival pathways, cell growth and metabolism, and immune-mediated tumorigenesis, respectively. Here, we further characterize the role of Neu1 in cancer cell signaling, as well as tumor growth, neovascularization and metastasis. Furthermore, the molecular targeting of Neu1 using competitive inhibitor and sialic acid analog oseltamivir phosphate (OP) has been evaluated for its therapeutic role in suppressing tumor progression.
This report uncovers the molecular mechanisms that regulate the role of Neu1 sialidase in insulin receptor activation. Specifically, we show that GPCR agonists bombesin, bradykinin, angiotensin I and angiotensin II can stimulate Neu1 sialidase activity to induce IR activation (phosphorylation) in the absence of insulin. Furthermore, this effect can be blocked by GPCR inhibitor BIM-23127 as well as OP.
The studies in this report also investigated the effect of OP in murine models of human triple-negative breast cancer (MDA-MB-231), ovarian endometrial cancer (A2780), and pancreatic ductal adenocarcinoma (PANC1) tumor xenografts growing in RAGxCγ mice. In comparison to untreated groups, OP treatment resulted in a significant reduction in tumor volume, metastatic spread to the mouse liver and lungs, as well as a reduction in tumor-associated neovascularization and recruitment of host endothelial cells. In conclusion, these findings provide insight into the novel targeting of tumor-promoting pathways via Neu1 sialidase and implicate OP as a novel agent in cancer therapy.
Description
Citation
Publisher
License
Queen's University's Thesis/Dissertation Non-Exclusive License for Deposit to QSpace and Library and Archives Canada
ProQuest PhD and Master's Theses International Dissemination Agreement
Intellectual Property Guidelines at Queen's University
Copying and Preserving Your Thesis
This publication is made available by the authority of the copyright owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted by the copyright laws without written authority from the copyright owner.
ProQuest PhD and Master's Theses International Dissemination Agreement
Intellectual Property Guidelines at Queen's University
Copying and Preserving Your Thesis
This publication is made available by the authority of the copyright owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted by the copyright laws without written authority from the copyright owner.